Preferred antiretroviral drugs for the next decade of scale up

Hdl Handle:
http://hdl.handle.net/10144/280933
Title:
Preferred antiretroviral drugs for the next decade of scale up
Authors:
Andrieux-Meyer, Isabelle; Calmy, Alexandra; Cahn, Pedro; Clayden, Polly; Raguin, Gilles; Katlama, Christine; Vitoria, Marco; Levin, Andrew; Lynch, Sharonann; Goemaere, Eric; Ford, Nathan
Journal:
Journal of the International AIDS Society
Abstract:
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their national guidelines to start ART earlier, for both clinical and preventive benefits. To maximize the benefits of ART in resource-limited settings, six key principles need to guide ART choice: simplicity, tolerability and safety, durability, universal applicability, affordability and heat stability. Currently available drugs, combined with those in late-stage clinical development, hold great promise to simplify treatment in the short term. Over the longer-term, newer technologies, such as long-acting formulations and nanotechnology, could radically alter the treatment paradigm. This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings.
Affiliation:
Médecins Sans Frontières, Geneva, Switzerland.
Issue Date:
18-Sep-2012
URI:
http://hdl.handle.net/10144/280933
PubMed ID:
23010379
Language:
en
ISSN:
1758-2652
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorAndrieux-Meyer, Isabelleen_GB
dc.contributor.authorCalmy, Alexandraen_GB
dc.contributor.authorCahn, Pedroen_GB
dc.contributor.authorClayden, Pollyen_GB
dc.contributor.authorRaguin, Gillesen_GB
dc.contributor.authorKatlama, Christineen_GB
dc.contributor.authorVitoria, Marcoen_GB
dc.contributor.authorLevin, Andrewen_GB
dc.contributor.authorLynch, Sharonannen_GB
dc.contributor.authorGoemaere, Ericen_GB
dc.contributor.authorFord, Nathanen_GB
dc.date.accessioned2013-04-11T22:15:50Z-
dc.date.available2013-04-11T22:15:50Z-
dc.date.issued2012-09-18-
dc.identifier.citationPreferred antiretroviral drugs for the next decade of scale up. 2012, 15 (2):17986 J Int AIDS Socen_GB
dc.identifier.issn1758-2652-
dc.identifier.pmid23010379-
dc.identifier.urihttp://hdl.handle.net/10144/280933-
dc.description.abstractGlobal commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their national guidelines to start ART earlier, for both clinical and preventive benefits. To maximize the benefits of ART in resource-limited settings, six key principles need to guide ART choice: simplicity, tolerability and safety, durability, universal applicability, affordability and heat stability. Currently available drugs, combined with those in late-stage clinical development, hold great promise to simplify treatment in the short term. Over the longer-term, newer technologies, such as long-acting formulations and nanotechnology, could radically alter the treatment paradigm. This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Journal of the International AIDS Societyen_GB
dc.subject.meshAnti-Retroviral Agentsen_GB
dc.subject.meshAntiretroviral Therapy, Highly Activeen_GB
dc.subject.meshGuidelines as Topicen_GB
dc.subject.meshHIV Infectionsen_GB
dc.subject.meshHumansen_GB
dc.titlePreferred antiretroviral drugs for the next decade of scale upen
dc.contributor.departmentMédecins Sans Frontières, Geneva, Switzerland.en_GB
dc.identifier.journalJournal of the International AIDS Societyen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.